Skip to main content
. 2020 Jun 17;8(8):2592–2599.e3. doi: 10.1016/j.jaip.2020.06.001

Table II.

Pediatric asthma burden during the COVID-19 pandemic

Pediatric asthma burden Overall cohort COVID-19 burden (deaths/million)
P Clinical setting
P
<10 10-100 >100 Primary Secondary Tertiary
No. of participants contributing data, N 61 22 10 23 13 9 34
Asthma control: What percentage of your pediatric asthma patients are currently
 Well controlled 70 (60-80) 80 (70-90) 70 (60-85) 60 (50-80) <.01 80 (80-90) 70 (65-80) 70 (60-80)
 Partially controlled 20 (10-30) 20 (10-20) 20 (15-30) 20 (20-30) 20 (10-20) 20 (20-35) 20 (10-30)
 Uncontrolled 10 (0-10) 10 (0-10) 10 (0-10) 10 (10-20) 0 (0-10) 10 (10-15) 10 (10-13)
Asthma control: How does the current control of your patients compare with your expectations for these patients?
 Better than expected 20 (10-40) 30 (10-50) 20 (10-25) 20 (10-40) 35 (20-43) 25 (10-48) 20 (10-30)
 As expected 85 (70-100) 90 (65-100) 80 (70-95) 80 (70-100) 90 (65-100) 90 (75-100) 80 (70-100)
 Worse than expected 10 (8-13) 10 (0-10) 10 (10-10) 10 (10-20) 0 (0-8) 10 (3-18) 10 (10-20) .03
Risk ratio of better vs worse asthma control, RR (99% CI) 2.69 (2.17-3.34) 5.19 (3.06-8.81) 2.90 (1.89-4.47) 1.99 (1.50-2.64) 12.67 (5.29-30.32) 4.00 (1.30-12.33) 2.07 (1.65-2.61)
What proportion of your patients required a change in their asthma treatments?
 Treatment escalation 10 (10-30) 10 (10-30) 10 (10-20) 20 (10-25) 10 (10-30) 15 (10-30) 10 (10-30)
 Unchanged treatment 80 (60-90) 80 (60-90) 80 (80-85) 80 (60-90) 90 (70-90) 80 (65-90) 80 (60-90)
 Treatment de-escalation 10 (0-20) 10 (0-20) 10 (0-10) 10 (0-20) 10 (0-10) 10 (5-15) 10 (0-20)
Risk ratio escalation vs deescalation, RR (99% CI) 1.41 (1.21-1.65) 1.78 (1.27-2.50) 5.21 (3.15-8.60) 0.95 (0.79-1.16) 2.22 (1.52-3.25) 2.42 (1.05-5.55) 1.24 (1.04-1.47)
Have you observed changes in the adherence to controller medications?
 Increased adherence 20 (10-43) 20 (10-30) 25 (13-38) 30 (10-50) 30 (20-45) 10 (8-15) 20 (10-50)
 Unchanged adherence 80 (60-100) 90 (70-100) 80 (60-100) 70 (53-100) 70 (65-95) 100 (95-100) 80 (50-100) .03
 Reduced adherence 10 (0-10) 10 (0-10) 10 (5-10) 10 (0-30) 10 (3-10) 0 (0-3%) 0 (0-18%)
Risk ratio of increased vs reduced adherence, RR (99% CI) 1.97 (1.66-2.33) 3.00 (2.01-4.47) 3.79 (2.41-5.98) 1.43 (1.16-1.77) 3.11 (2.08-4.64) 6.00 (0.38-94.23) 1.73 (1.43-2.09)
Limited availability/access to asthma medications, n (%) 21/69 (30) 8/25 (32) 2/15 (33) 9/25 (36) 6/15 (40) 3/11 (28) 12/42 (29)

Values are median (IQR) unless otherwise indicated.